Eisai

Eisai (pronounced 'ā-zī') is derived from the Japanese word for 'health product', and here at Eisai, we discover, develop and market innovative, high quality medicines throughout the world.

We place primary emphasis on patients and their families and observe the highest legal and ethical standards in our business activities.

Eisai is one of the world's leading research-based pharmaceutical companies.

We define our corporate mission as "giving first thought to patients and their families, and to increasing the benefits health care provides," which we call human healthcare (hhc).

Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology. Our Neurology franchise includes treatments for disorders such as epilepsy and insomnia and our Oncology franchise includes treatments for cancers such as metastatic breast cancer, differentiated thyroid cancer, hepatocellular carcinoma, endometrial carcinoma and liposarcoma.

For more information about Eisai, or our products, please visit www.eisai.com.au or email contact_australia@eisai.net.

For clinician resources please visit eisaipro.com.au.

For any medical information enquiries, please contact Eisai Australia medical information at medinfo_australia@eisai.net, or on 03 9832 9100. Suspected adverse events can be reported at www.tga.gov.au/reporting-problems, or directly to Eisai at safety_australia@eisai.net.